Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.06Last Year’s EPS
0.05Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -28.13%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic advancements, particularly in high-potential accounts and the BLA process for Avance Nerve Graft. However, challenges such as a decline in gross margin, delayed hiring for the breast segment, and the inability to implement process improvements until after BLA approval were noted. Overall, the positive aspects, including revenue growth and strategic execution, outweigh the challenges.Company Guidance
During the call, Axogen provided guidance for the full year 2025, maintaining expectations for revenue growth in the range of 15% to 17%. The company reported that its revenue for the first quarter of 2025 increased by 17.4% to $48.6 million, driven by a 14% increase in unit volume and a 3% increase in price. Despite a decline in gross margin from 78.8% to 71.9% year-over-year, Axogen anticipates a full-year gross margin between 73% and 75%, factoring in approximately $2 million in one-off costs related to the BLA approval. The company plans to be cash flow positive for the year and expects to self-fund its strategic plan through cash from operations. Axogen also highlighted strategic initiatives, including expanding its commercial infrastructure and focusing on high-potential accounts, which exceeded productivity targets in the first quarter. The company is progressing with the BLA process for its Avance Nerve Graft, expecting approval in September and the resulting 12-year market exclusivity.Strong Revenue Growth
Revenue in the first quarter of 2025 increased to $48.6 million, up 17.4% compared to last year, driven by continued adoption of Axogen's nerve repair algorithm across target markets.
High-Potential Accounts Performance
The company exceeded its target of generating 66% growth from high-potential accounts, driven by a 24% increase in average account productivity versus a plan of 21%.
Expansion of Commercial Infrastructure
Multiple strategic hires were completed across sales, marketing, and market access teams to strengthen capabilities and capacity.
Progress on BLA for Avance Nerve Graft
The BLA process remains on track with successful clinical trial site inspections and FDA meetings, expecting approval in September for market exclusivity.
Improved Financial Metrics
Net loss reduced to $3.8 million from $6.6 million in the first quarter of 2024, with adjusted EBITDA increasing to $2.9 million from $1 million.
---
AXGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AXGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $16.39 | $12.59 | -23.18% |
Feb 25, 2025 | $18.01 | $20.11 | +11.66% |
Nov 07, 2024 | $15.33 | $13.27 | -13.44% |
Aug 08, 2024 | $7.92 | $10.70 | +35.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AxoGen (AXGN) report earnings?
AxoGen (AXGN) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is AxoGen (AXGN) earnings time?
AxoGen (AXGN) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AXGN EPS forecast?
AXGN EPS forecast for the fiscal quarter 2025 (Q2) is 0.06.
---